miR‑210‑3p regulates cell growth and affects cisplatin sensitivity in human ovarian cancer cells via targeting E2F3

  • Authors:
    • Yue Jin
    • Jun Wei
    • Shaoting Xu
    • Fang Guan
    • Lijun Yin
    • Haibin Zhu
  • View Affiliations

  • Published online on: April 4, 2019     https://doi.org/10.3892/mmr.2019.10129
  • Pages: 4946-4954
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The potential role of microRNA (miR)‑210‑3p in carcinogenesis and the cisplatin sensitivity of ovarian cancer were evaluated in the present study. The relative expression levels of miR‑210‑3p in cisplatin‑sensitive SKOV‑3 cells and cisplatin‑resistant SKOV‑3/DDP cells were determined using reverse transcription‑quantitative polymerase chain reaction analysis. miR‑210‑3p mimics and inhibitors were transfected into SKOV‑3/DDP cells. Cell Counting Kit‑8, scratch and Transwell invasion assays and flow cytometry were conducted to evaluate the role of miR‑210‑3p in ovarian cancer cells. A luciferase reporter assay was used to verify the association between miR‑210‑3p and E2F transcription factor 3 (E2F3). Drug sensitivity was evaluated by treating the cells with cisplatin. The expression level of miR‑210‑3p was lower in SKOV‑3/DDP cells than in SKOV‑3 cells. Compared with the untransfected control, SKOV‑3 cells transfected with miR‑210‑3p exhibited a significantly higher survival rate. The overexpression of miR‑210‑3p inhibited SKOV‑3/DDP cell proliferation, migration and invasion, and promoted cell apoptosis. By contrast, the inhibition of miR‑210‑3p promoted cell migration and invasion. The luciferase reporter assay confirmed that E2F3 was a direct target gene of miR‑210‑3p. Cisplatin treatment resulted in a sharp decrease in the survival rate of SKOV‑3/DDP cells transfected with the miR‑210‑3p mimics. The decrease in cell survival rate caused by the overexpression of miR‑210‑3p was rescued by the overexpression of E2F3 in SKOV‑3/DDP cells. Taken together, these results suggest that miR‑210‑3p may act as a tumor suppressor in ovarian cancer cells and affect the sensitivity of cells to cisplatin by directly targeting E2F3. This indicates its potential use as a therapeutic target for improving drug resistance in ovarian cancer.

References

1 

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI

2 

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI

3 

Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI

4 

Davis A, Tinker AV and Friedlander M: ‘Platinum resistant’ ovarian cancer: What is it, who to treat and how to measure benefit? Gynecol Oncol. 133:624–631. 2014. View Article : Google Scholar : PubMed/NCBI

5 

Wang J and Sen S: MicroRNA functional network in pancreatic cancer: From biology to biomarkers of disease. J Biosci. 36:481–491. 2011. View Article : Google Scholar : PubMed/NCBI

6 

Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI

7 

Chan SY and Loscalzo J: MicroRNA-210: A unique and pleiotropic hypoxamir. Cell Cycle. 9:1072–1083. 2010. View Article : Google Scholar : PubMed/NCBI

8 

Vera O, Jimenez J, Pernia O, Rodriguez-Antolin C, Rodriguez C, Sanchez Cabo F, Soto J, Rosas R, Lopez-Magallon S, Esteban Rodriguez I, et al: DNA methylation of miR-7 is a mechanism involved in platinum response through MAFG overexpression in cancer cells. Theranostics. 7:4118–4134. 2017. View Article : Google Scholar : PubMed/NCBI

9 

Chen W, Du J, Li X, Su J, Huang Y, Ding N, Zhang M and Jiang S: miR-509-3p promotes cisplatin-induced apoptosis in ovarian cancer cells through the regulation of anti-apoptotic genes. Pharmacogenomics. 18:1671–1682. 2017. View Article : Google Scholar : PubMed/NCBI

10 

Zhang S, Zhang JY, Lu LJ, Wang CH and Wang LH: MiR-630 promotes epithelial ovarian cancer proliferation and invasion via targeting KLF6. Eur Rev Med Pharmacol Sci. 21:4542–4547. 2017.PubMed/NCBI

11 

Han X, Zhang Y, Wang D, Fu X, Li M and Wang A: Upregulation of microRNA-18b induces phosphatase and tensin homolog to accelerate the migration and invasion abilities of ovarian cancer. Oncol Lett. 14:5631–5637. 2017.PubMed/NCBI

12 

Giannakakis A, Sandaltzopoulos R, Greshock J, Liang S, Huang J, Hasegawa K, Li C, O'Brien-Jenkins A, Katsaros D, Weber BL, et al: miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther. 7:255–264. 2008. View Article : Google Scholar : PubMed/NCBI

13 

Xu Y, Wang C, Su J, Xie Q, Ma L, Zeng L, Yu Y, Liu S, Li S, Li Z and Sun L: Tolerance to endoplasmic reticulum stress mediates cisplatin resistance in human ovarian cancer cells by maintaining endoplasmic reticulum and mitochondrial homeostasis. Oncol Rep. 34:3051–3060. 2015. View Article : Google Scholar : PubMed/NCBI

14 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

15 

Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, Ang KK, Story M, Le QT and Giaccia AJ: Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell. 35:856–867. 2009. View Article : Google Scholar : PubMed/NCBI

16 

Malzkorn B, Wolter M, Liesenberg F, Grzendowski M, Stühler K, Meyer HE and Reifenberger G: Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol. 20:539–550. 2010. View Article : Google Scholar : PubMed/NCBI

17 

Puissegur MP, Mazure NM, Bertero T, Pradelli L, Grosso S, Robbe-Sermesant K, Maurin T, Lebrigand K, Cardinaud B, Hofman V, et al: miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ. 18:465–478. 2011. View Article : Google Scholar : PubMed/NCBI

18 

Ren D, Yang Q, Dai Y, Guo W, Du H, Song L and Peng X: Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-κB signaling pathway. Mol Cancer. 16:1172017. View Article : Google Scholar : PubMed/NCBI

19 

Tsuchiya S, Fujiwara T, Sato F, Shimada Y, Tanaka E, Sakai Y, Shimizu K and Tsujimoto G: MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1). J Biol Chem. 286:420–428. 2011. View Article : Google Scholar : PubMed/NCBI

20 

Yang X, Shi L, Yi C, Yang Y, Chang L and Song D: MiR-210-3p inhibits the tumor growth and metastasis of bladder cancer via targeting fibroblast growth factor receptor-like 1. Am J Cancer Res. 7:1738–1753. 2017.PubMed/NCBI

21 

Nakashima S, Jinnin M, Kanemaru H, Kajihara I, Igata T, Okamoto S, Tazaki Y, Harada M, Masuguchi S, Fukushima S, et al: The role of miR-210, E2F3 and ephrin A3 in angiosarcoma cell proliferation. Eur J Dermatol. 27:464–471. 2017.PubMed/NCBI

22 

Yoshino H, Yonemori M, Miyamoto K, Tatarano S, Kofuji S, Nohata N, Nakagawa M and Enokida H: microRNA-210-3p depletion by CRISPR/Cas9 promoted tumorigenesis through revival of TWIST1 in renal cell carcinoma. Oncotarget. 8:20881–20894. 2017. View Article : Google Scholar : PubMed/NCBI

23 

Li L, Huang K, You Y, Fu X, Hu L, Song L and Meng Y: Hypoxia-induced miR-210 in epithelial ovarian cancer enhances cancer cell viability via promoting proliferation and inhibiting apoptosis. Int J Oncol. 44:2111–2120. 2014. View Article : Google Scholar : PubMed/NCBI

24 

Vandamme B, Lissens W, Amfo K, De Sutter P, Bourgain C, Vamos E and De Grève J: Deletion of chromosome 11p13-11p15.5 sequences in invasive human ovarian cancer is a subclonal progression factor. Cancer Res. 52:6646–6652. 1992.PubMed/NCBI

25 

Viel A, Giannini F, Tumiotto L, Sopracordevole F, Visentin MC and Boiocchi M: Chromosomal localisation of two putative 11p oncosuppressor genes involved in human ovarian tumours. Br J Cancer. 66:1030–1036. 1992. View Article : Google Scholar : PubMed/NCBI

26 

Vaksman O, Stavnes HT, Kaern J, Trope CG, Davidson B and Reich R: miRNA profiling along tumour progression in ovarian carcinoma. J Cell Mol Med. 15:1593–1602. 2011. View Article : Google Scholar : PubMed/NCBI

27 

Reimer D, Hubalek M, Riedle S, Skvortsov S, Erdel M, Concin N, Fiegl H, Müller-Holzner E, Marth C, Illmensee K, et al: E2F3a is critically involved in epidermal growth factor receptor-directed proliferation in ovarian cancer. Cancer Res. 70:4613–4623. 2010. View Article : Google Scholar : PubMed/NCBI

28 

Reimer D, Hubalek M, Kiefel H, Riedle S, Skvortsov S, Erdel M, Hofstetter G, Concin N, Fiegl H, Müller-Holzner E, et al: Regulation of transcription factor E2F3a and its clinical relevance in ovarian cancer. Oncogene. 30:4038–4049. 2011. View Article : Google Scholar : PubMed/NCBI

29 

Song L, Duan P, Gan Y, Li P, Zhao C, Xu J, Zhang Z and Zhou Q: MicroRNA-340-5p modulates cisplatin resistance by targeting LPAATbeta in osteosarcoma. Braz J Med Biol Res. 50:e63592017. View Article : Google Scholar : PubMed/NCBI

30 

Yi DY, Su Q, Zhang FC, Fu P, Zhang Q, Cen YC, Zhao HY and Xiang W: Effect of microRNA-128 on cisplatin resistance of glioma SHG-44 cells by targeting JAG1. J Cell Biochem. 119:3162–3173. 2018. View Article : Google Scholar : PubMed/NCBI

31 

Li ZH, Zhang H, Yang ZG, Wen GQ, Cui YB and Shao GG: Prognostic significance of serum microRNA-210 levels in nonsmall-cell lung cancer. J Int Med Res. 41:1437–1444. 2013. View Article : Google Scholar : PubMed/NCBI

32 

Zhao HM, Wei W, Sun YH, Gao JH, Wang Q and Zheng JH: MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells. Tumour Biol. 36:6867–6873. 2015. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 19 Issue 6

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Jin, Y., Wei, J., Xu, S., Guan, F., Yin, L., & Zhu, H. (2019). miR‑210‑3p regulates cell growth and affects cisplatin sensitivity in human ovarian cancer cells via targeting E2F3. Molecular Medicine Reports, 19, 4946-4954. https://doi.org/10.3892/mmr.2019.10129
MLA
Jin, Y., Wei, J., Xu, S., Guan, F., Yin, L., Zhu, H."miR‑210‑3p regulates cell growth and affects cisplatin sensitivity in human ovarian cancer cells via targeting E2F3". Molecular Medicine Reports 19.6 (2019): 4946-4954.
Chicago
Jin, Y., Wei, J., Xu, S., Guan, F., Yin, L., Zhu, H."miR‑210‑3p regulates cell growth and affects cisplatin sensitivity in human ovarian cancer cells via targeting E2F3". Molecular Medicine Reports 19, no. 6 (2019): 4946-4954. https://doi.org/10.3892/mmr.2019.10129